source
- Novo outlines diversification strategy with new pipeline assets and bolt-on dealsNovo Pharmaceuticals' chief executive Maziar Mike Doustdar used the company's recent capital-markets day in London to lay out a diversification plan. He said the rebranded firm will focus on expand…
- Cue Biopharma's chronic hives drug clears Phase 2 trial, first immunology data after cancer pivotCue Biopharma announced that its candidate for chronic spontaneous urticaria successfully completed a Phase 2 trial in China. The trial marks the company's first clinical data since it shifted its…